China Medical System (HKG:0867) has obtained approval for clinical trials of its CMS-D005 injection from China's National Medical Products Administration, a Wednesday bourse filing said.
The pharmaceutical innovation and commercialization company can conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of the drug in healthy and overweight/obese adult subjects in China.
CMS-D005 can be developed in the future to treat obesity/overweightedness, metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and other metabolism-related diseases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。